Last reviewed · How we verify
Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ppsv23 | ppsv23 | Pfizer | Vaccine | Streptococcus pneumoniae |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older:
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older treatment updates — RSS
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older treatment updates — Atom
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-50-years-of-age-or-older. Accessed 2026-06-10.
Related
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing